Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5208]

IPSO guidelines on minimally invasive surgery in paediatric solid tumours

Dr Israel Fernandez-Pineda - Children’s Health Ireland at Crumlin, Dublin...

IPSO guidelines on minimally invasive surgery in paediatric solid tumours ( Dr Israel Fernandez-Pineda - Children’s Health Ireland at Crumlin, Dublin, Ireland )

Shaping the future: advancing HR-NMIBC management beyond BCG

Dr Laura Mertens, Dr Marco Moschini and Prof Evanguelos Xylinas

Shaping the future: advancing HR-NMIBC management beyond BCG ( Dr Laura Mertens, Dr Marco Moschini and Prof Evanguelos Xylinas )

Do all hormone sensitive prostate cancers need triplet therapy?

Dr Deepak Dabkara - Tata Medical Center, Kolkata, India

Do all hormone sensitive prostate cancers need triplet therapy? ( Dr Deepak Dabkara - Tata Medical Center, Kolkata, India )

Choosing Wisely: ctDNA/ Precision Oncology in colorectal cancers

Dr Aparna Parikh - Massachusetts General Hospital, Boston, EE.UU

Choosing Wisely: ctDNA/ Precision Oncology in colorectal cancers ( Dr Aparna Parikh - Massachusetts General Hospital, Boston, EE.UU )

I-DXd shows strong brain metastasis responses in extensive-stage small cell...

Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain

I-DXd shows strong brain metastasis responses in extensive-stage small cell lung cancer with manageable safety ( Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain )

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous...

Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain

Tarlatamab for SCLC: Subgroup analysis shows benefit regardless of previous chemo or anti-PD-(L)1 use ( Dr Pedro Rocha - Vall d'Hebron University Hospital, Barcelona, Spain )

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Tarlatamab improves symptoms and QoL over chemo in previously treated SCLC ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior...

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece

Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )

Temab-A plus bevacizumab shows promising response rates in advanced colorectal...

Dr Michael Cecchini - Yale School of Medicine, New Haven, USA

Temab-A plus bevacizumab shows promising response rates in advanced colorectal cancer ( Dr Michael Cecchini - Yale School of Medicine, New Haven, USA )

ESMO 2025: Latest developments in endometrial cancer

Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth

ESMO 2025: Latest developments in endometrial cancer ( Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth )

ESMO 2025: Latest in mRCC

Dr Javier Puente, Prof Jens Bedke, Prof Laurence Albiges and Prof Viktor...

ESMO 2025: Latest in mRCC ( Dr Javier Puente, Prof Jens Bedke, Prof Laurence Albiges and Prof Viktor Grünwald )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

More from ecancer